MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Foghorn Therapeutics, Inc.

< Previous 1 2 Next >
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Participate in the BMO Oncology Summit
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story